RRML - Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17


Advanced search


Top 10 downloaded articles
- December 2022 -
 
Downregulation of hsa-miR-4328... 5
Normality assessment, few para... 4
Setting up an own laboratory p... 3
The relationship between matri... 2
New Para-Clinical Investigatio... 2
New high-throughput liquid chr... 2
General Principles of Haematop... 2
Genetic risk factors for throm... 2
The importance of the new prog... 2
Detection of chromosomal imbal... 2

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 30(3)/2022 DOI:10.2478/rrlm-2022-0026
XML
TXT

Research article

Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis

Yan Xu, Xianqiu Yu, Xinlong Zhang

Correspondence should be addressed to: Xinlong Zhang

Abstract:

Background: To study the expressions of transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF) in patients with acute myeloid leukemia (AML) and their values for prognosis. Methods: A total of 120 AML patients treated from January 2015 to December 2018 were selected. Bone marrow mononuclear cells were isolated. The expressions of TGF-β1 and VEGF were detected by RT-PCR, and their associations with clinical characteristics were analyzed. The overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method. The risk factors for prognosis were analyzed through the Cox proportional hazards model. Results: The AML group had significantly lower relative expression of TGF-β1 and higher relative expression of VEGF than those of the control group (P<0.05). TGF-β1 and VEGF levels were significantly correlated with white blood cell count, hemoglobin, platelets, and peripheral blood juvenile cells (P<0.05). TGF-β1 level was higher and VEGF level was lower in the patients with complete response than those in the patients with partial response and no response (P<0.05). Both OS and DFS of the patients with high TGF-β1 expression were better than those of the patients with low TGF-β1 expression, while they were also superior among the patients with low VEGF expression (P<0.05). Platelets, TGF-β1 and VEGF were independent influencing factors for OS, and white blood cells, TGF-β1 and VEGF were independent influencing factors for DFS (P<0.05). Conclusions: AML patients have decreased expression of TGF-β1 and increased expression of VEGF, and such changes are closely associated with the prognosis of AML.

Keywords: TGF-β1, VEGF, acute myeloid leukemia, prognosis

Received: 26.11.2021
Accepted: 6.6.2022
Published: 14.6.2022

 
  PDF Download full text PDF
(785 KB)
     
 
How to cite
Xu Y, Yu X, Zhang X. Expressions of TGF-β1 and VEGF in patients with acute myeloid leukemia and associations with prognosis. Rev Romana Med Lab. 2022;30(3):273-80. DOI:10.2478/rrlm-2022-0026